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Abstract
Conflicting data exist regarding the association between pre-operative monoclonal anti-tumor
necrosis factor-alpha antibody therapy with infliximab for Crohn disease and chronic ulcerative
colitis, and the occurrence of post-operative complications. This report reviews the current
literature that supports and refutes this association.
Introduction and context
Gastroenterologists and surgeons who specialize in the
treatment of Crohn disease (CD) and chronic ulcerative
colitis (CUC) have become increasingly aware of the
implications of different forms of medical therapy on
surgical outcomes. This is especially important in the era
of ‘top-down’ and multi-agent therapy for inflammatory
bowel disease (IBD) [1, 2]. Although relatively little
literature exists regarding the relationship between pre-
operative corticosteroid use and post-operative compli-
cations, several authors have found that increasingly
higher doses of such immunosuppressive medications
may result in an increased rate of post-operative septic
complications [3, 4]. Similarly, there is increasing
concern that combination immunomodulatory therapy
with multiple agents may also be associated with an
increase in post-operative infectious complications
[5, 6]. Given reports of the association of monoclonal
anti-tumor necrosis factor-alpha (anti-TNF-a) antibody
therapy with pulmonary infections, this concern has
specifically been focused on infliximab (IFX), which
until recently has been the only FDA-approved biologic
agent for IBD [7-11].
A recent meta-analysis of the association between
immunomodulatory therapy and post-operative com-
plications after surgery for IBD, which included studies
of azathioprine, cyclosporine A, and three studies of IFX,
found that the available evidence did not support this
association [12]. Since then, several studies have been
published suggesting that IFX is indeed associated with
an increased risk of post-operative complications [12].
Thus, the potential association between IFX and surgical
complications is controversial; studies both support and
refute this potential relationship [5,13–19]. This F1000
Medicine Report will review the major findings of these
studies.
Recent advances
Crohn disease
In a study of 270 patients by Colombel et al. [14], 52
patients experienced intra-abdominal septic complica-
tions (IASCs) after bowel resection for CD. Analysis did
not reveal any increased risk in the IFX-treated subgroup,
the moderate-to-high-dose corticosteroid subgroup, or
the immunomodulator subgroup. Likewise, a matched
case-control study from Belgium of 31 CD patients also
concluded that pre-operative IFX use did not result in a
significantly increased rate of post-operative complica-
tions, or increased hospital length of stay, as compared
to a control group of IFX-naïve patients [15]. That study
did note, however, a trend towards increased early post-
operative infections in the IFX group. More recently, a
study of 413 IBD patients (156 with CD), of which 101
had received IFX within 12 weeks of surgery, also did not
find any relationship between pre-operative IFX therapy
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similar to others, was relatively limited by the absolute
number of complications.
In contrast, a more recent study from Appau et al. [17]
found an association between pre-operative IFX therapy
for CD and post-operative complications. They con-
cluded that IFX therapy within 3 months of surgery was
associated with an increased rate of IASCs, and of
hospital re-admissions. They also found that patients
who received a diverting stoma had a lower risk of IASCs,
thus prompting the observation that a diverting stoma
may be prudent when surgeons are faced with CD
patients who have recently received IFX. In light of this
study, the risks associated with stoma reversal surgery
must be weighted against the potential increase in
complications associated with IFX for CD.
Chronic ulcerative colitis
In a study of 151 patients with CUC, 17 (10%) of whom
failed IFX therapy and went to surgery and 134 of whom
were IFX-naïve, no association between IFX and compli-
cations was observed [5]. However, the authors observed
that IFX patients who had concurrent cyclosporine A
treatment were at increased risk for overall and infectious
complications.
In a larger study by Selvasekar et al. [16] in which 47 CUC
patients received pre-operative [ileal pouch-anal anasto-
mosis (IPAA)] IFX therapy and 254 did not, those who
received IFX were more likely to have anastomotic leak,
and after multivariate adjustment for both disease
severity and other medication use, IFX remained
independently associated with an increased risk of ileal
pouch-related and infectious complications [16]. Finally,
a recent study of 85 patients with CUC who received IFX
pre-operatively also found that patients who receive pre-
operative IFX were at increased risk of post-operative
septic complications as well as late complications [19].
Importantly, the authors also noted that patients who
received IFX were more likely to have undergone a 3-
stage IPAA, likely due to surgeon reluctance to perform
an anastomosis in the setting of pre-operative IFX
administration.
Common limitations
Many of these retrospective studies suffer from common
limitations. First is lack of adjustment for disease severity
(Table 1). Disease severity determined retrospectively is
Table 1. Summary of literature of the association of IFX with post-operative complications
Article Institution Year IBD IFX subjects/Total
subjects
IFX window Specifically
adjusted for
disease
severity
IFX increased
complications?
Comments
Colombel [14] Mayo Clinic,
Rochester
2004 CD 52/270 (19%) 8 weeks
before to
4 weeks
after surgery
No No Multivariate adjustment for steroid
use showed no increase in
complications for IFX or combination
immunosuppressive therapy patients.
Trend towards increased complica-
tions with pre-operative steroids
Marchal [15] University
Hospital,
Gasthuisberg
2004 CD 31/313 (10%) 12 weeks No No Univariate analysis showed no
increase in post-operative length of
stay or complications, but trend
towards increased early
post-operative complications
Appau [17] Cleveland
Clinic, Ohio
2008 CD 60/389 (15%) 3 months No Yes Multivariate adjustment (6 covariates)
showed increase in post-operative
sepsis, abscess, and readmissions.
Stoma use decreased rate of sepsis
Schluender [5] Cedars Sinai 2007 CUC 17/151 (11%) 1–12 months No No Univariate analysis showed no
increase unless combined with
cyclosporine A. Study likely
underpowered
Selvasekar [16] Mayo Clinic,
Rochester
2007 CUC 47/301 (16%) 6 months Yes Yes Multivariate adjustment (4 covariates)
showed increased pouch-related and
infectious complications
Mor [19] Cleveland
Clinic, Ohio
2008 CUC 85/523 (16%) 4–37 weeks Yes Yes Multivariate adjustment (5 covariates)
showed increased risk for both
2-stage and 3-stage IPAA
Kunitake [18] Mass General 2008 Both 101/413 (24%) 12 weeks No No Multivariate adjustment (3 covariates)
showed IFX patients had a longer
hospital stay. No difference seen
between CD and CUC patients
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inadequate substitutions for validated methods of
assessing disease activity. However, it is interesting to
note that in the studies of CUC, those that adjusted for
disease activity showed a relationship between IFX and
complications, while the converse was true for those
studies that did not. Another major limitation of several
of these studies is the relatively long pre-operative IFX
window, often 12 weeks or more (Table 1). Recent
studies of the pharmacokinetics of IFX in IBD suggest
that the elimination half-life is between 7 and 18.5 days
[20, 21]. By 12 weeks (84 days, or 4.5 half-lives), most
IBD patients should have undetectable levels of IFX.
A window of 12 weeks used by several of the studies
published to date may theoretically produce negative
results regarding the occurrence of post-operative out-
comes if a significant proportion of patients had an
interval this long between IFX administration and
surgery. Ideally, the duration between last infusion and
surgery should be included as a continuous variable, but
outpatient infusion often makes these data unavailable
retrospectively.
Referral practice patterns may too account in part for
the heterogenous findings of these studies, as these may
differ substantially in various regions of the world, as
demonstrated by at least a 10% variation in the
proportion of surgical IBD patients who received IFX.
Thus, as is usually true of most retrospective studies,
results from a single institution may not be broadly
generalizable; the institutions themselves may be con-
sidered as a potential confounding factor when compar-
ing results of different studies to each other.
In one of the largest studies of the association of IFX and
serious infections and mortality, the TREAT Registry
study of 6290 patients found that after adjustment for
corticosteroid use and disease severity, IFX was not
independently associated with increased risk, although
both corticosteroids and disease severity were associated
with those adverse outcomes [22]. Although this study
did not include surgical endpoints, the implications
are nonetheless important, especially given the lack of
large-scale surgical data.
Implications for clinical practice
Whether pre-operative IFX use is associated with post-
operative complications after surgery for IBD remains
controversial; current evidence favors this association
after surgery for CUC but does not favor an increased risk
after surgery for CD. The potentially practice-changing
implications of this debate are occurring now; increas-
ingly some surgeons are waiting until anti-TNF-a agents
are washed out before operating or, if that is not
possible, performing resections for CD with temporary
diverting stomas or advising 3- rather than 2-staged
IPAA.
Larger studies and/or formal meta-analysis of the
relationship between IFX and post-operative complica-
tions after surgery for IBD are needed before definitive
treatment recommendations can be made. The decision
of whether or not to perform staged surgery for IBD
patients on IFX needs to be made on an individual basis,
based on the clinical context and other known risk
factors, such as hypoalbuminemia and high-dose corti-
costeroid treatment.
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